MedTrace Logo

Safety and Efficacy of STSP-0601 in Adult Patients With Hemophilia A or B Without Inhibitor

NCT05619926 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2024-01-02

No results posted yet for this study

Summary

This study will assess the safety,efficacy,pharmacokinetics and pharmacodynamics of multiple-dose of STSP-0601 at two dose levels for the treatment of bleeding episodes in hemophilia A or B patients without inhibitor.

Conditions

Interventions

DRUG

STSP-0601 for Injection

Intravenous Injection

Sponsors & Collaborators

  • Beijing Novikang Medical Technology Co., LTD

    collaborator UNKNOWN

  • Staidson (Beijing) Biopharmaceuticals Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Lei Zhang, MD · Affiliation:Hospital of Hematology, Chinese Academy of Medical Sciences

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-09
Primary Completion
2023-08-25
Completion
2023-08-25

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05619926 on ClinicalTrials.gov